ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Draig Therapeutics closed a $65 million Series B funding round. The company will use the capital to advance its pipeline of precision medicines. The financing supports clinical development and expansion of its platform.
Tap to vote and see what everyone thinks.
Summary by ByteBrief